aTyr Pharma (NASDAQ:ATYR) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

aTyr Pharma (NASDAQ:ATYR - Free Report) had its target price boosted by Wells Fargo & Company from $17.00 to $25.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

Separately, HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of aTyr Pharma in a research report on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $20.20.

aTyr Pharma Price Performance

ATYR traded down $0.24 during trading on Friday, reaching $4.98. The stock had a trading volume of 2,946,063 shares, compared to its average volume of 1,085,544. The firm has a market capitalization of $443.22 million, a price-to-earnings ratio of -6.15 and a beta of 0.88. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 1-year low of $1.46 and a 1-year high of $5.98. The stock has a 50 day moving average of $4.03 and a two-hundred day moving average of $3.67.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. As a group, equities analysts anticipate that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

Large investors have recently added to or reduced their stakes in the company. Group One Trading LLC acquired a new stake in aTyr Pharma during the 4th quarter valued at $26,000. Victory Capital Management Inc. acquired a new stake in aTyr Pharma during the 4th quarter valued at $37,000. Raymond James Financial Inc. acquired a new position in shares of aTyr Pharma in the fourth quarter worth $39,000. XTX Topco Ltd acquired a new position in shares of aTyr Pharma in the fourth quarter worth $40,000. Finally, Two Sigma Advisers LP acquired a new position in shares of aTyr Pharma in the fourth quarter worth $44,000. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.